PSI Webinar(s): Causal inference in Clinical Trials
Over the course of two sessions, a panel of 8 esteemed speakers will give an introduction to the topic, followed by a presentation of case studies & interactive panel discussion.
Our objectives include:
This corner is created to discuss Real World Data (RWD) topics coming from industry, academia and Health Authorities.
Blog Posts:
Let's T@lk Real: DAGs 5th December 2023
Let's T@lk Real: What are RWD 3rd July 2023
Let's T@lk Real: External Controls 22nd May 2023
Let's T@lk Real: Survey 19th December 2022
SIG Member | Organisation |
---|---|
Allessandro Guasconi | Chiesi Farmaceutici S.p.A. |
Antonio Remiro-Azocar | Bayer |
Barbara Torlinska | Visible Analytics Ltd. / University of Birmingham |
Deepak Parashar | Warwick University |
Eleanor Ralphs | IQVIA |
Elizabeth Merrall | Janssen |
Emma Martin | Phastar |
Fiona Grimson | UCB |
Gilles Guillot | CSL Behring |
Helen Broadhurst | Plus-Project |
Huajun Wang | GSK Vaccines |
Jessica Ackerman | Responsum Health |
Jixian (Jason) Wang | Bristol Myers Squibb |
Josie Wolfram (Co-chair) | Astellas |
Laura Day | Vitaccess |
Min-Hua Jen | Eli Lilly |
Qing Wang | Roche |
Rachel Tham | Veramed |
Rima Izem (Co-chair) | Novartis |
Roxane Debrus | Genmab |
Savina Jaeger | Spark Therapeutics |
Stefano Viaggi | ICON plc |
Sudhir Venkatesan | Astra Zeneca |
Tobias Bluhmki | Bristol Myers Squibb |
Victoria Strauss | Boehringer Ingelheim |
Yulia Dyachkova | Merck |
We also have an observer/informed member list who are included on meeting invites and mails, but we don’t expect active contributions nor list you on the SIG page members list. Shifting status to active is then welcomed any time!
Call for members
If you are interesting in joining the RWD SIG please contact Josie Wolfram or Rima Izem.
Monthly teleconferences
Over the course of two sessions, a panel of 8 esteemed speakers will give an introduction to the topic, followed by a presentation of case studies & interactive panel discussion.
In a world buzzing with artificial intelligence, can you distinguish between what's AI-generated and what's not? The session promises to showcase machine-generated content, challenging your perceptions, and luring you into the fascinating world of AI technology.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
This course consists of 5 x 2 hour training sessions run over 5 weeks. For those who cannot attend the date and time provided, there will be a recording provided and a follow-up 1 hour Q and A session. Participation will provide access to extensive course materials in the form of a “bookdown” site. However, this is designed as a hands-on, interactive course. Both you and the trainers will work entirely within the RStudio Cloud development environment, which will remain accessible between virtual sessions in order to further explore and cement your understanding.
The Pre-Clinical SIG Workshop returns for 2024, bringing you a two half-days event, starting with a course on pre-clinical design of experiments. We will also have speakers on topics such as statistics and genetic toxicology, the new and promising OMARS DOE and ANOVA-type.
Are you a member of PSI looking to further your career or help develop others - why not sign up to the PSI Mentoring scheme? You can expand your network, improve your leadership skills and learn from more senior colleagues in the industry.
Suitable for PhD candidates in statistics or a related discipline. Full-time for 10-12 weeks in Summer 2024. Remote working, from the United States or the United Kingdom
UCB invites TWO candidates interested in a career in drug development to undertake a medical statistician apprenticeship.
The Principal DMC Statistician works primarily in the production and quality control.
Head of Respiratory Vaccines Clinical Statistics role has portfolio leadership for statisticians aligned to vaccine development in the area of Respiratory disease, providing statistical leadership for Clinical Development and Commercialization.
BioMarin is the world leader in delivering therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases.